Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a person’s ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July 2024. With its earlier launch, much of the real-world data at AD/PD ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

Within the past few years, the FDA approved two groundbreaking drugs that in trials were shown to reduce brain plaque by 27% ...

Leqembi is an infusion therapy approved by the Food and Drug Administration in 2023. It targets and removes the beta-amyloid ...

The legislation would require insurance plans provided through the state’s system to cover FDA-approved treatments for ...

Leqembi collected sales of 29.6 billion Japanese yen (about $194 million) over the last nine months of 2024, putting it on track to reach a 12-month sales target of 42.5 billion Japanese yen ($279 ...